What Gets Under Patients Skin: Integrating Subcutaneous Immune Checkpoint Inhibitor Formulations into the Management of Solid Tumors in Oncology Practice

The expansion of immune checkpoint inhibitors (ICIs) across solid tumors has renewed focus on the logistical burden of repeated intravenous (IV) infusions for patients, caregivers, and oncology practices. As treatment durations lengthen and eligible populations grow, oncology practices face increasing strain on infusion capacity, patient travel burdens, and staffing resources. Emerging data on subcutaneous (SQ) ICI formulations show pharmacokinetic equivalence, manageable safety, and the potential to streamline care without sacrificing outcomes. These developments create a timely opportunity to rethink ICI delivery and to align treatment efficacy with greater patient-centered efficiency. This program aims to translate published evidence and recent authorizations related to SC ICIs into practical, patient-centered decision-making for oncology teams. Videorecorded segments from individuals that received IV and/or SC ICIs are interwoven with faculty perspectives on this information, helping clinicians apply evidence to individualized planning and to the safe, efficient implementation of SC ICIs across practice settings.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Cross-Specialty

Patient Safety & Quality Improvement

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
Credit · Up to 0.5 credits
Commercial Support

Released

Dec 29, 2025
Last day to claim credit

Dec 30, 2026 3 months left

What Gets Under Patients Skin: Integrating Subcutaneous Immune Checkpoint Inhibitor Formulations into the Management of Solid Tumors in Oncology Practice

Related courses

More from Partners for Advancing Clinical Education